Biofrontera Inc. (NASDAQ: BFRI) announced that it locked the database for its Phase 1 pharmacokinetics study of Ameluz on February ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE